Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
about
Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones?Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsMechanisms of drug resistance: daptomycin resistanceNew Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological MalignanciesDaptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococciDaptomycin in paediatrics: current knowledge and the need for future researchActivity of Fosfomycin- and Daptomycin-Containing Bone Cement on Selected Bacterial Species Being Associated with Orthopedic Infections.Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE)Deletion of liaR Reverses Daptomycin Resistance in Enterococcus faecium Independent of the Genetic BackgroundClinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents.Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence.Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant EnterococciTreatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin.Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditiRapid Turbidimetric Assay to Determine the Potency of Daptomycin in Lyophilized Powder.Comparative evaluation of VITEK® 2 and three commercial gradient strip assays for daptomycin susceptibility testing of Staphylococcus aureus.Daptomycin.Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible Vancomycin-Resistant Enterococcus
P2860
Q26745991-4DEC45E6-B479-4E6B-ACB9-2539E946CD04Q26752922-9DD108EB-F88B-41F4-BE41-B282032DC0F0Q26779944-2C64971D-4F2A-4944-B67B-943BBDF4EF14Q26799580-C664650A-CAAA-46A9-8B4B-E09574448730Q26851754-CAD9B7F8-6C72-4B00-A356-BB23372E2F35Q27006038-3743E6D2-5AAD-482A-9A93-1F6E037828F0Q33581795-D540FB26-C6E1-407F-AA7A-D66869F6241BQ34503844-53ADF941-6A4F-458B-8CD4-CED791A3A74DQ35385108-09F211D6-4B38-4D1A-A5CE-72C7C25B344BQ35746209-E5C293A2-015E-4395-A22E-87F4B9DCD8D0Q35974360-C1C9DE2F-9477-4E9D-A55A-97D7E864CCE4Q36073400-D80E2B54-B250-44DB-A935-EA2F9BD0B665Q36290600-D9271B05-7638-421E-9482-D75FCDD13941Q36795603-64573D91-5605-4D75-ADC7-61287AF917CBQ37023118-A8F01EC2-D212-4219-B9CC-8839B798B583Q38263421-680C7141-4D64-4792-9301-7EAFAEAD6B1BQ38347869-E0ECCC8A-9651-443F-8A25-F09D8FF6AA06Q38828204-CEC6CFCF-93C3-487F-BF86-4E0396CC3119Q39016281-78C06E79-4536-4F9B-B369-BDC3AD9FBD95Q39168565-53F43C88-F243-4F61-851C-DAF528C8FE9BQ39516822-5C9557EF-A13B-4BE6-B48B-6FEDDE1FCDBDQ40105754-5AF29D2B-B9EE-427E-AA90-7E7CBB3F2508Q40330828-80354A07-9CFE-40E7-8BD1-99192CB3817CQ41610683-A9DC9D41-9AE3-423A-AD81-000576522021Q41992968-E26055C3-FE63-4AE4-BBE0-74F264842F1EQ47616115-8D029E4B-3FB8-4760-9B20-6CE49EA1D49CQ57480754-7AA969A6-B84A-4F9B-BEE2-38F6C92724C2
P2860
Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Daptomycin activity tested aga ...... illance Programme (2005-2012).
@en
Daptomycin activity tested aga ...... rldwide Surveillance Programme
@nl
type
label
Daptomycin activity tested aga ...... illance Programme (2005-2012).
@en
Daptomycin activity tested aga ...... rldwide Surveillance Programme
@nl
prefLabel
Daptomycin activity tested aga ...... illance Programme (2005-2012).
@en
Daptomycin activity tested aga ...... rldwide Surveillance Programme
@nl
P1476
Daptomycin activity tested aga ...... illance Programme (2005-2012).
@en
P2093
David J Farrell
Ronald N Jones
P304
P356
10.1016/J.IJANTIMICAG.2014.01.018
P577
2014-02-17T00:00:00Z